Synthesis, functional proteomics and biological evaluation of new 5-pyrazolyl ureas as potential anti-angiogenic compounds.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Dec 2021
Historique:
received: 19 07 2021
revised: 09 09 2021
accepted: 24 09 2021
pubmed: 3 10 2021
medline: 27 1 2022
entrez: 2 10 2021
Statut: ppublish

Résumé

Based on biological results of previous synthesized pyrazolyl ureas able to interfere with angiogenesis process, we planned and synthesized the new benzyl-urea derivatives 2-4; some of them showed an interesting anti-proliferative profile and particularly 4e potently inhibited HUVEC proliferation. To shed light on the mechanism of action of 4e, its interactome has been deeply inspected to identify the most prominent protein partners, mainly taking into account kinome and phosphatome, through drug affinity responsive target stability experiments, followed by targeted limited proteolysis analysis. From these studies, PP1γ emerged as the most reliable 4e potential target in HUVEC. Molecular docking simulations on PP1γ were carried out to predict 4e binding mode. To assess its potential anti-angiogenic effect, 4e was tested in vitro to verify interference on kinase and phosphate activities. Overall, our results evidenced for 4e an interesting anti-angiogenic action, probably due to its action at intracellular level on PP1γ signalling pathways.

Identifiants

pubmed: 34600191
pii: S0223-5234(21)00721-2
doi: 10.1016/j.ejmech.2021.113872
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Pyrazoles 0
Urea 8W8T17847W
Protein Phosphatase 1 EC 3.1.3.16

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113872

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Elva Morretta (E)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084, Fisciano, Salerno, Italy.

Adama Sidibè (A)

Department of Cell Physiology and Metabolism, University of Geneva, Rue Michel-Servet 1, CH - 1211, Geneva, Switzerland.

Andrea Spallarossa (A)

Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genova, Viale Benedetto XV 3, 16132 Genova, Italy.

Antonello Petrella (A)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084, Fisciano, Salerno, Italy.

Elda Meta (E)

Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie, Leuven, Belgium.

Olga Bruno (O)

Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genova, Viale Benedetto XV 3, 16132 Genova, Italy.

Maria Chiara Monti (MC)

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084, Fisciano, Salerno, Italy.

Chiara Brullo (C)

Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genova, Viale Benedetto XV 3, 16132 Genova, Italy. Electronic address: brullo@difar.unige.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH